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Abstract 
Internal ribosome entry sites (IRES elements) have attracted interest in cancer gene therapy 
because they can be used in the design of gene transfer vectors that provide bicistronic 
co-expression of two transgene products under the control of a single promoter. Unlike cellular 
translation of most mRNAs, a process that requires a post-translational 5' modification of the 
mRNA known as the cap structure, IRES-mediated translation is independent of the cap structure. 
The cellular conditions that may intervene to modulate IRES-mediated, cap-independent versus 
cap-dependent translation, however, remain poorly understood, although they could be critical to 
the choice of gene transfer vectors. Here we have compared the effects of the p14ARF (Alternate 
Reading Frame) tumor suppressor, a translational suppressor frequently overexpressed in cancer, 
on cap-dependent translation versus cap-independent translation from the EMCV viral IRES often 
used in bicistronic gene transfer vectors. We find that ectopic overexpression of p14ARF 
suppresses endogenous and ectopic cap-dependent protein translation, consistent with other 
studies. However, p14ARF has little or no effect on transgene translation initiated within an IRES 
element. This suggests that transgenes placed downstream of an IRES element will retain efficient 
translation of their gene products in the presence of high levels of ectopic or endogenous p14ARF, 
a finding that could be particularly relevant to therapeutic gene therapy strategies for cancer. 
Key words: p14ARF, Internal ribosome entry site (IRES), cap-dependent, protein translation. 
Introduction 
Initiation of protein translation from an internal 
ribosome entry site (IRES) is an alternative type of 
protein translation in which ribosomes are recruited 
directly to an mRNA by virtue of its secondary 
structure, independently of the 5' modification of the 
mRNA known as the cap structure, a modification 
required for the recruitment of the translation 
initiation factor protein (eIFs) to most cellular RNAs 
(see review [1-3]). IRES often eliminates the 
involvement of eIFs, activated by binding to specific 
sets of proteins, referred to as IRES trans-acting 
factors (ITAFs). IRES-mediated translation was first 
described in poliovirus RNA and 
encephalomyocarditis virus (EMCV) RNA [4, 5] ,and 
is now thought to contribute to the translation of 
certain cellular RNAs as well, particularly under 
abnormal cellular states triggered by hypoxia or 
cellular stress [6]. So far, multiple IRES were 
identified with different mechanisms in translational 
regulation. They may or may not use eIFs and ITAFs 
to recruit the ribosome to the message. 








increasingly attractive as a tool in biotechnology 
because it provides a means to achieve bicistronic 
co-expression of transduced genes under the control 
of a single transcriptional promoter. When an IRES 
segment is located between two genes in a eukaryotic 
mRNA molecule, it can drive translation of the 
downstream protein coding region independently of 
the 5'-cap structure bound to the message. 
Nevertheless, the regulation of IRES-mediated 
translation has not been fully explored and remains 
poorly understood.  
In this study we asked how IRES-mediated 
translation is affected by the 14ARF (alternate reading 
frame) tumor suppressor, a translational repressor [7] 
induced in cells with activated oncogenes [8, 9]. 
p14ARF could inhibit the polysome formation and 
protein synthesis by interacting with the nucleolar 60 
S preribosomal particle [6]. p14ARF expression is 
undetectable in most normal cells, but evidence 
suggests that its levels increase at an early stage of 
tumorigenesis [10] and elevated p14ARF levels have 
been observed in certain cancers [11-13]. This 
increased expression could therefore affect the 
outcome of some therapeutic gene transfer strategies.  
Because of the differences in the mechanisms by 
which CAP-dependent and IRES-mediated, 
CAP-independent translation are initiated, it seemed 
possible that p14ARF could have differential effects 
on these two modes of translation that could be 
relevant to use of IRES-containing gene transfer 
vectors. We report here our finding that messages 
translated from IRES elements display little or no 
suppression by p14ARF, suggesting that 
IRES-mediated translation may be particularly useful 
for gene therapy applications in certain cancers where 
p14ARF expression is high.  
When multiple tumor suppressor genes are used 
in cancer gene therapy simultaneously, they 
sometimes interfere with each other. Our study 
proposed a model that when two tumor suppressor 
genes are constructed in one expression cassette 
containing IRES element, the IRES could protect the 
downstream gene from the inhibition induced by 
upstream gene, and this will make a common sense 
for other genes. Therefore, if we need to employ 
multiple tumor suppressor genes in gene therapy and 
to avoid the mutual interference, it is better to put 
genes in one cassette and introduce IRES between the 
genes, instead of applying two genes separately. 
Materials and methods 
Cell culture 
 All cultures were maintained at 37oC in 10% CO2 
in Dulbecco’s Modified Eagles Medium 
supplemented with nonessential amino acids, 
pyruvate, L-glutamine, gentamicin, and 10% FBS. 
DLD-1 human colon cancer cells were obtained from 
the Americian Type Culture Collection. OE33 human 
esophageal cancer cells originated from the European 
Collections of Cell cultures and were provided to us 
by Dr. Rebecca Fitzgerald, Cambridge University, UK. 
To obtain OE33-GFP and OE33-IRES-GFP, we stably 
modified OE33 cells with plasmid constructs 
pLXSN-GFP (for OE33-GFP) and pLXSN-IRES-GFP 
(for OE33-IRES-GFP), in which GFP message is 
translated in a cap-dependent or cap-independent 
manner, respectively. The GFP and IRES (ECMV) 
sequences were derived from pIRES-GFP (Clontech, 
Mountainview, CA). pLXSN was obtained from 
Clontech, Mounainview, CA. GFP-expressing clones 
were selected in G418 followed by cell sorting. Mouse 
Embryo Fibroblasts, nullizygous for p53 and mdm2, 
were generously provided by Dr. Guillermina 
Lozano, Department of Molecular Genetics, the 
University of Texas M.D. Anderson Cancer Center, 
Houston, TX.  
Vectors and treatment conditions 
The replication-defective adenoviral vectors, 
AdLuc, encoding firefly luciferase, and Adp53, 
encoding the human p53 tumor suppressor gene, 
were purchased from Vector Biolabs, Philadelphia, 
PA. The replication-defective adenoviral vectors, 
Adp14, encoding the human p14ARF (Alternate 
Reading Frame) tumor suppressor gene, and 
Adp14/p53, encoding both human p14ARF and p53 
in a bicistronic configuration, have been described 
[14]. Cells were treated with adenoviral vectors for 4 
hours with 50-100 plaque-forming units (pfu) per cell 
in culture medium containing 2% serum, as 
previously described [14]. Human mdm2 siRNA was 
purchased from Dharmacon (Chicago, Il). For siRNA 
treatments, 4 x106 adenoviral vector-treated cells were 
subjected to electroporation (200V) in the presence of 
150 pmol siRNA. 
Western analysis 
Western analyses were carried out using 40 µg 
cell lysates as previously described [14, 15] using 
mouse monoclonal anti-human mdm2 SMP14 (Santa 
Cruz Biotechnology, Santa Cruz, CA).  
Metabolic labeling and fluorography 
GFP-expressing OE33-GFP and OE33-IRES-GFP 
cells were metabolically labeled for 1 hour with 
[35S]-L-methionine (1175 Ci/mmol, MP Biomedicals, 
Solon, OH), followed by immunoprecipitation of GFP 
protein, SDS-PAGE and fluorography as previously 
described [16, 17]. Mouse monoclonal anti-GFP 
antibody was obtained from Santa Cruz 




Biotechnology, Santa Cruz, CA).  
Polysome fractionation and analysis 
Post-mitochondrial cytoplasmic fractions were 
sedimented on 17 ml 10-50% sucrose gradients 
following published procedures [18]. 1.5 ml fractions 
were collected and RNA was extracted and analyzed 
by semi-quantitative RT-PCR as previously described 
[14, 15]. p53 primers have been previously described 
[19]. The RT-PCR products were resolved on a 1.0% 
agarose gel stained with ethidium bromide, and band 
intensities were quantitated digitally and represented 
as a percent of total intensity. Results of each 
polysome analysis were confirmed by at least one 
independent repeat experiment. 
Results and Discussion 
The total level of a given protein subjects to two 
events, synthesis and degradation. It is known that 
p14ARF has a specific effect on p53 protein stability 
by binding with mdm2, the major inhibitor of p53 
[20], therefore, our study focused on detection of the 
rates of p53 synthesis rather than total accumulation. 
Rates of protein are related to the number of 
ribosomes per message, with rapidly synthesized 
proteins being derived from messages that are heavily 
occupied with ribosomes and that sediment more 
rapidly. Alternatively, rates of protein synthesis rates 
are related to the incorporation of [35S]-methionine 
during a pulse.  
We first investigated how overexpressed ectopic 
p14ARF affects the translation rate of an endogenous 
gene by examining the distribution of endogenous 
p53 message in polysomes from p14ARF-transduced 
DLD-1 human colon cancer cells, following 
sedimentation of post-mitochondrial cytoplasmic 
fractions on sucrose density gradients. A typical 
sedimentation profile of polysomes from DLD-1 cells, 
monitored by absorbance at 260 nm, is shown in 
Figure 1a, where those with heavier ribosome 
occupation appear in the rapidly sedimenting 
polysome region towards the right of the profile, and 
60S ribosomal subunit of 80S initiation complex 
located in the left. The staining profile of ribosomal 
RNA is shown underneath it. Figure 1b shows the 
distribution of endogenous p53 message in polysomes 
of DLD-1 cells 24 hours post-treatment with 50 
plaque-forming units (pfu) per cell of either a control 
replication-defective adenoviral vector encoding 
firefly luciferase (AdLuc) or a replication-defective 
adenoviral vector encoding p14ARF (Adp14). As we 
have previously reported, expression of p14ARF 
protein in DLD-1 cells is low to undetectable [14]. 
Treatment with Adp14 leads to about a 20-fold 
increase in p14ARF message levels by 24 hours post 
treatment, and results in readily detectable levels of 
p14ARF protein on Western blots (data not shown). 
Suppression of cell viability by Adp14 treatment only 
becomes evident after 72 hours [14]. We found that in 
cells treated with AdLuc, endogenous p53 message 
was broadly distributed across the polysome profile, 
peaking in fraction 5, indicating efficient recruitment 
of message to the heavier polysome region and 
efficient translation. In contrast, in cells treated with 
Adp14, endogenous p53 message shifted to the left of 
the profile, peaking in fraction2, a region occupied by 
monosomes and small polysomes associated with 
slowly translated messages (Figure 1b). Figure 1c 
shows the correspondent polysome profiles from the 
cells treated with Adluc and Adp14. Thus, 
endogenous p53 message is less efficiently translated 
in cells overexpressing ectopic p14ARF, consistent 
with previous reports that p14ARF can inhibit 
translation initiation [7]. 
However, a different result was observed when 
we examined ectopic expression of p53 following 
treatment of DLD-1 cells with a bicistronic adenoviral 
vector encoding both p14ARF and p53 in a single 
transcript (Adp14/p53), where the p53 open reading 
frame is situated downstream of an 
encephalomyocarditis virus (EMCV) internal 
ribosome entry site (IRES). We found that in DLD-1 
cells treated either with Adp14/p53 or with the 
Adp53 single gene vector (Figure 2a), the ectopic p53 
message was broadly distributed across the polysome 
profile, both peaking in fraction 5. Relative polysome 
profiles for the vector treatment were shown in Figure 
2b. Treatment conditions, as previously shown, were 
such that p53 message levels increased by some 
20-fold by 24 hours post-treatment of DLD-1 cells 
with either Adp53 or Adp14/p53 [14]. Message levels 
of p14ARF also increased by some 20-fold in 
Adp14/p53-treated cells [14].  
We ruled out a possible role of the mdm2 protein 
in maintaining p53 translation rates in 
Adp14/p53-treated cells. The mdm2 gene is induced 
by p53 [21], and mdm2 protein can in turn stimulate 
p53 translation [22]. Induced mdm2 could therefore 
potentially offset the possible negative effects of 
over-expressed ectopic p14ARF. However, we found 
that siRNA treatment to downregulate mdm2 protein 
levels in Adp14/p53-treated cells by 48 hours 
post-treatment (Figure 2c, lane 4 versus lane 3) had no 
effect on the 48 hour polysome distribution of ectopic 
p53 (Figure 2a). This indicates that the translation of 
p53 from the bicistronic construct is intrinsically less 
susceptible p14ARF-mediated translational 
suppression than is translation of the endogenous p53 
transcript, independently of mdm2. 





Figure 1. Effect of p14ARF on endogenous p53 translation in DLD-1 human colon cancer cells. (a) Typical O.D.260 profile of fractionated polysomes 
and ribosomal RNA staining profile from 2 x 107 DLD-1 cells. Arrow indicates direction of sedimentation. (b) Distribution of endogenous p53 message in fractions 
of polysomes, prepared from 2 x 107 DLD-1 cells 24 hours post-treatment (50 pfu/per cell, 4 hours) with AdLuc control vector or Adp14. Fractions (1.5 ml) were 
collected from the top of the gradient, RNA was purified, and subjected to semi-quantitative RT–PCR analysis of p53. (c) Relative polysome profiles from the cells 
treated with Adluc and Adp14. 
 
 
Figure 2. Effect of p14ARF on ectopic p53 translation in DLD-1 human colon cancer cells. Distribution of ectopic p53 message in various polysome 
fractions from 4 x 106 DLD-1 cells, 48 hours post-treatment (50 pfu/cell, 4 hours) with Adp53, or Adp14/p53 bicistronic vector , or with Adp14/p53 bicistronic vector 
followed by electroporation with human mdm2 siRNA. (b) Relative polysome profiles for all the adenovirus treatment, seperately. (c) Western analysis of human 
mdm2 protein expression in DLD-1 cells, 48 hours after treatment with the indicated vectors +/- mdm2 siRNA.  
 
We therefore considered the possibility that the 
failure of p14ARF to suppress ectopic p53 translation 
in Adp14/p53-treated cells derived from the 
characteristics of the bicistronic vector itself, and in 
particular, the presence of the IRES in the bicistronic 
vector and the fact that translation from an IRES 
element was cap-independent, while translation of the 
endogenous message was cap-dependent. To test this, 
we used p14ARF and p53 single gene and bicistronic 
adenoviral vectors that would allow us to compare 
these two modes of translation for ectopic p53 under 
similar conditions (see diagram in Figure 3a). 
Translation of ectopic p53 message was monitored in 
p53/mdm2 doubly nullizygous mouse embryo 
fibroblasts (DN-MEFs), which lack endogenous p53 
message. Polysome analyses were carried out 24 
hours post-treatment with (a) Adp53 alone, where p53 
translation is cap-dependent, or (b) with a 
combination of Adp53 plus Adp14, or (c) with the 
Adp14/p53 bicistronic vector, where p53 translation 
is cap-independent. Treatment conditions for Adp14 
or Adp14/p53 were 100 pfu/cell and produced the 




same level of p14ARF protein (Figure 3b). We found 
that ectopic p53 message in Adp53-treated DN-MEFs 
was efficiently translated, as indicated by the broad 
distribution of message across the polysome profile, 
peaking in fraction 5 (Figure 3c). The results are 
consistent with the results with Adp53-treated DLD-1 
cells (Figure 2a). We found that ectopic p53 message 
was less efficiently translated in Adp53 + 
Adp14-treated DN-MEFs, as indicated by the shift in 
the polysome distribution of ectopic p53 message 
toward the left of the gradient, peaking in fraction 2 
(Figure 3c). Thus, cap-dependent translation of 
ectopic p53 is less efficient in the presence of 
overexpressed ectopic p14ARF. In contrast, we found 
that ectopic p53 message in Adp14/p53-treated 
DN-MEFs, was efficiently translated, despite the 
overexpression of p14ARF, as indicated by the 
polysome profile peaking in fraction 5 (Figure 3c). The 
profile is similar to that observed with Adp53-treated 
DN-MEFs and Adp14/p53-treated DLD-1 cells. Thus, 
IRES-mediated, cap-independent translation of 
ectopic p53 is efficient, even in the presence of 
overexpressed ectopic p14ARF. 
To confirm and extend these observations to 
another cell line and to another gene, and to use a 
different method to evaluate protein synthesis rates, 
we prepared stably-modified variants of the OE33 
human esophageal adenocarcinoma cell line, in which 
the Green Fluorescent Protein (GFP) gene was placed 
either downstream of a viral LTR promoter 
(OE33-GFP, providing cap-dependent translation of 
GFP) or an IRES (OE33-IRES-GFP, providing 
cap-independent translation of GFP). The two 
modified clones were treated with Adp14 (100 
pfu/cell) and 2 days later the rate of GFP protein 
synthesis was monitored by pulsing cells with 
[35S]-methionine, followed by SDS/PAGE and 
fluorography of immunoprecipitated GFP. A typical 
fluorograph of [35S]-methionine incorporation into 
GFP is shown in Figure 4a, where each lane represents 
105 cell equivalents. A bar graph representing an 
average of two experiments is shown in Figure 4b. A 
Western blot confirming that p14ARF was induced to 
similar levels 24 hours post-infection of both cell lines 
is shown in Figure 4c. The results show that 
cap-dependent translation of GFP in OE33-GFP cells 
modified with an LTR-GFP construct is suppressed on 
the average by some 90% in Adp14 treated cells 
compared to AdLuc-treated cells (Figure 4b, black 
bar), while cap-independent translation of GFP in 
OE33-IRES-GFP cells modified with an IRES-GFP 
construct shows only weak to no suppression by 
Adp14 (Figure 4b, gray bar). The ability of 
IRES-mediated protein translation to escape 
suppression by p14ARF appears therefore to be a 
general phenomenon with potential relevance to any 




Figure 3. Effect of p14ARF on cap-dependent versus cap-independent translation of p53 in p53-null, mdm2-null MEFs (DN-MEFs). (a) Diagram 
illustrating the two modes of p53 translation achieved with either the bicistronic adenoviral vector, Adp14/p53 (top), where p53 is translated from the IRES in a 
cap-independent manner, or the p53 single gene vector, Adp53 (bottom), where p53 message is expressed from the CMV promoter and translated in a 
cap-dependent manner. (b) Western blot of p14ARF protein levels in untreated DN-MEFs (control), and in DN-MEFs, 24 hours post-treatment with 100 pfu/cell of 
Adp14 or Adp14/p53. Each lane represents 40 µg cellular lysates. (c) Distribution of ectopic p53 message in various fractions of polysomes from 4 x 106 p53/mdm2 
doubly nullizygous mouse embryo fibroblasts (DN-MEFs), 24 hours after treatment with Adp53 alone (100 pfu/cell), or with a combination of Adp53 plus Adp14 single 
gene vectors (100 pfu/cell each), or with Adp14/p53 bicistronic vector (100 pfu/cell).  





Figure 4. Effect of p14ARF on cap-dependent versus cap-independent GFP translation in OE33 human esophageal adenocarcinoma cells. (a) 
GFP protein synthesized in OE33-GFP and OE33-IRES-GFP cells during a 1-hour pulse with [35S]-methionine carried out 24 hours post-infection with AdLuc or 
Adp14 at 100 pfu/cell, followed by immunoprecipitation with anti-GFP, SDS-PAGE and fluorography. Each lane represents 105 cell equivalents. (b) Bar graph 
representing the average of two [35S]-methionine uptake experiments described in part (A). Bars represent average incorporation of [35S]-methionine into GFP in 
Adp14-treated cells relative to AdLuc-treated cells, with standard deviations shown. (c) Western blot of p14ARF protein levels in AdLuc-treated or Adp14-treated 
OE33-GFP and OE33-IRES-GFP, 24 hours post-treatment with 100 pfu/cell of Adp14 or Adp14/p53. each lane represents 40 µg cellular lysates. 
 
Multiple tumor suppressor genes and molecular 
pathways have been disrupted in cancer. However, 
the current strategy of cancer therapy usually focuses 
on repairing a particular gene or pathway, leading to 
a limited therapeutic effect. p53 and p14ARF have 
been reported to be loss of function in about 50% and 
40% of cancer patients separately. In our study, we 
choose p53 and p14ARF as our selected target, and 
our results suggest that for gene transfer applications 
where p14ARF is co-expressed with another 
transgene, it may be necessary to place the second 
transgene downstream of an IRES element to insure 
maximum expression of its gene product. Similarly, 
for cancer cells with a disabled apoptotic pathways, 
and characterized by high level expression of 
endogenous p14ARF due to chronic oncogene 
activation, it may be necessary to employ gene 
transfer vectors that incorporate IRES elements in 
order to ensure maximum transgene expression 
following gene transfer. However, we didn’t check 
other viral IRES types, whether our conclusion 
applied to EMCV IRES only, or other IRES elements, 
is still unknown. 
Further studies will be needed to determine 
whether selective suppression of cap-dependent 
translation by p14ARF involves a specific interaction 
of p14ARF with a translational regulatory protein, 
and whether cellular IRES elements are also resistant 
to p14ARF-mediated translational suppression. In 
preliminary work, we have been unable to find 
evidence for the binding of p14ARF to the eIF4E 
binding protein, an upstream regulator of the eIF4E 
translation initiation factor, suggesting that p14ARF 
does not exert its differential effects via the eIF4E 
initiation complex (Huang Y., et al, unpublished 
observations).  
Conclusions 
From the conclusion of our study, we can use the 
Adp14/p53 in which two tumor suppressor genes 
were expressed in one cassette including IRES for 
colon cancer treatment, and achieve a significant 
effect of tumor suppression. Also, the ability of 
p14ARF to selectively suppress cap-dependent 
translation could have broader relevance to cellular 
regulation. CAP-independent translation from 
cellular IRES elements, though normally weak [23], is 
emerging as an important cellular mechanism for 
maintaining expression of critical gene products 
under conditions where cap-dependent translation is 
suppressed, for example during the cellular stress 
response [24]. Thus the induction and subcellular 
redistribution of p14ARF in response to certain types 
of DNA damage [17, 25] could have a dual 
consequences for the cellular stress response, the first 
involving its well-described role in stabilizing the p53 
protein, and the second involving selective 
suppression of cap-dependent protein translation 
followed by a redirection of cellular translation 




towards IRES-mediated translation of stress response 
proteins. 
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